[Clinical significance of mustoforan in management of malignant glioma].
Kobiakov
G L
GL
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001254:Astrocytoma / Q000188:drug therapy; D001812:Blood-Brain Barrier / Q000187:drug effects; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D002330:Carmustine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009837:Oligodendroglioma / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012673:Semustine / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D012673:Semustine; D008130:Lomustine; C054368:fotemustine; D002330:Carmustine